Optimising In Vivo Tumour Models for Translational Success: Exploring Strategies to Overcome Preclinical Oncology Modelling Limitations
- Evaluating in vivo systems for small molecules and immuno-oncology agents, and identifying factors that influence predictive accuracy
- Addressing common pitfalls such as overinterpretation and variability in terminated studies to refine efficacy assessment
- Implementing strategies to improve data relevance, including better understanding of tumour microenvironment and immune interactions